Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Bloom

Pulmonary Disease Annandale, VA Medical Doctor

NPI 1821014846 CMS profile 263594

Northern Virigina Pulmonary & Critical Care Assoc. Pc, 3289 Woodburn Road, 350, Annandale, VA 22003

Open in the dashboard

General payments

$4,106

219 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Bloom of Annandale, VA is reported in the CMS Open Payments database as having received $4,106 across 219 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22 1
2023 General $604 30
2022 General $1,610 77
2021 General $122 6
2020 General $322 18
2019 General $1,426 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Bloom
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Robert Bloom were reported at $22. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Robert Bloom Pulmonary Disease median Middle half National median
2019 $1,426 $377 $109–$1,340 $163
2020 $322 $230 $56–$907 $114
2021 $122 $269 $68–$1,072 $132
2022 $1,610 $390 $100–$1,457 $149
2023 $604 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $22 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $522 38 payments
  2. Genentech USA, Inc. $499 22 payments
  3. Genzyme Corporation $417 22 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $410 20 payments
  5. AstraZeneca Pharmaceuticals LP $352 24 payments
  6. Regeneron Healthcare Solutions, Inc. $175 7 payments
  7. Insmed, Inc. $165 9 payments
  8. Janssen Pharmaceuticals, Inc $154 8 payments
  9. Mylan Specialty L.P. $152 8 payments
  10. Mallinckrodt Hospital Products Inc. $94 3 payments
  11. Other $1,166 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,086 217 payments
  2. Education $20 2 payments
Products named General payments · program years 2019–2025
  1. Xolair $443 19 payments
  2. DUPIXENT Immunology $298 13 payments
  3. TRELEGY ELLIPTA $260 20 payments
  4. OFEV $234 11 payments
  5. DUPIXENT Immunology $221 15 payments
  6. SPIRIVA RESPIMAT $215 11 payments
  7. DUPIXENT Inflammation And Immunology $175 7 payments
  8. Arikayce $165 9 payments
  9. XARELTO $154 8 payments
  10. Esbriet $152 6 payments
  11. Other $2,248 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

413

Median for Internal Medicine: 777

Drug cost

$75,776

Median for Internal Medicine: $73,373

Branded share of claims

66.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 41 $26,981
Symbicort Budesonide/Formoterol Fumarate Brand 40 $10,081
Spiriva Respimat Tiotropium Bromide Brand 16 $10,029
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 14 $6,604
Fluticasone Propionate Hfa Fluticasone Propionate Brand 16 $4,746
Qvar Redihaler Beclomethasone Dipropionate Brand 20 $4,379
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 30 $4,182
Arnuity Ellipta Fluticasone Furoate Brand 12 $3,358
Breyna Budesonide/Formoterol Fumarate Brand 17 $2,740
Albuterol Sulfate Hfa Albuterol Sulfate Brand 56 $1,382

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$26,919

Medicare's payments for the services billed

Medicare patients

296

Average age 73

Services billed

568

181 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 51%
COPD 39%
Diabetes 27%
Depression 27%
Ischemic heart disease 25%
Osteoporosis 25%
Chronic kidney disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record